As we wrote in Prohost Letter #409, a transformation in this year’s American Society of Clinical Oncology meeting (ASCO) is further elaborating on Checkpoint inhibition and chimeric antigen receptor T-cell (CAR-T) approaches’ limitations. Both are attempts towards making Immunotherapy for cancer a successful treatment. Checkpoint inhibitors have reached the market at the hands of Merck, Bristo-Myers Squibb and Roche, with other firms coming forward with products in early-, mid- and late-Phase trials. No CAR-T products have been approved yet, but two approvals are expected this year for Kite (KITE) and . . .
This content is for paid subscribers.
Today’s Highlights June 6, 2017